Founded by Baylor College of Medicine faculty members with an exclusive license from the Baylor College of Medicine, StemMed is a pharmaceutical development and testing company adddressing advancement of the treatment of breast cancer through novel insights into the biology of the stem cells that cause the disease. Research shows that only a small subset of the heterogeneous cells within a malignant tumor are responsible for the initiation and maintenance of tumor growth. Therefore, StemMed principals judge firm that specifically targeting such cells for therapeutic intervention will inhibit tumor formation, growth and metastasis. Management judge that this approach may be particularly effective in the treatment of cancers that are resistant to conventional therapies
